BAY-57-1293
BAY-57-1293 Basic information
- Product Name:
- BAY-57-1293
- Synonyms:
-
- PRITELIVIR;AIC316
- Benzeneacetamide, N-[5-(aminosulfonyl)-4-methyl-2-thiazolyl]-N-methyl-4-(2-pyridinyl)-
- AIC316
- N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide BAY57-1293 Pritelivir
- 2-METHYL-2-PROPANYL [4-(CHLOROSULFONYL)PHENYL]CARBAMATE
- BAY571293(Pritelivir)
- BAY-57-1293
- Pritelivir
- CAS:
- 348086-71-5
- MF:
- C18H18N4O3S2
- MW:
- 402.49
- Product Categories:
-
- Inhibitors
- Mol File:
- 348086-71-5.mol
BAY-57-1293 Chemical Properties
- Boiling point:
- 639.4±65.0 °C(Predicted)
- Density
- 1.396±0.06 g/cm3(Predicted)
- storage temp.
- 2-8°C(protect from light)
- solubility
- insoluble in H2O; insoluble in EtOH; ≥13.9 mg/mL in DMSO
- form
- solid
- pka
- 9.31±0.60(Predicted)
- color
- White to off-white
- InChI
- InChI=1S/C18H18N4O3S2/c1-12-17(27(19,24)25)26-18(21-12)22(2)16(23)11-13-6-8-14(9-7-13)15-5-3-4-10-20-15/h3-10H,11H2,1-2H3,(H2,19,24,25)
- InChIKey
- IVZKZONQVYTCKC-UHFFFAOYSA-N
- SMILES
- C1(CC(N(C2=NC(C)=C(S(N)(=O)=O)S2)C)=O)=CC=C(C2=NC=CC=C2)C=C1
BAY-57-1293 Usage And Synthesis
Uses
BAY 57-1293 is a potent inhibitor of herpes simplex virus (HSV) that target the virus helicase primase complex.
Biological Activity
bay 57-1293 is a potent and safe inhibitor of hsv helicase-primase with ic50 value of 12nm [1].bay 57-1293 displays anti-herpes activity through inhibiting the helicase-primase and affecting the viral dna synthesis. in the in vitro viral replication assay, bay 57-1293 shows inhibition against hsv-1 f, hsv-2 g and acyclovir-resistant hsv-1 f mutant with ic50 value of 20nm. in the plaque reduction assay and the conventional cytopathogenicity assay, bay 57-1293 shows ic50 values of 0.01-0.02μm and 0.01-0.03μm, respectively. besides that, bay 57-1293 is active at an ic50 value of 10nm–30nm against all clinical isolates of hsv-1 and hsv-2. furthermore, bay 57-1293 is active in vivo. the oral administration of bay 57-1293 shows 10-fold more potent than valacyclovir in a murine model of disseminated herpes infection. in a rat lethal challenge model, bay 57-1293 exerts profound antiviral activity without toxic effects. [1, 2]
in vivo
Pritelivir is the first in a class of antiviral agents that inhibit HSV replication by targeting the viral helicase-primase enzyme complex[2].
Pritelivir (0.03-45 mg/kg) significantly increases survival. Pritelivir (0.3-30 mg/kg) reduces mortality against HSV-1, E-377. Pritelivir has potent and resistance-breaking antiviral efficacy with potential for the treatment of potentially life-threatening HSV type 1 and 2 infections, including herpes simplex encephalitis[3].
Combination therapies of Pritelivir at 0.1 or 0.3 mg/kg/dose with Acyclovir (10 mg/kg/dose) are protective when compared to the vehicle treated group against HSV-2, strain MS[3].
| Animal Model: | Female BALB/c mice[3] |
| Dosage: | 0.03 to 45 mg/kg |
| Administration: | Administered orally, twice daily at approximately 12 h intervals, for 7 days |
| Result: | Survival was significantly increased to 80-100% as compared to the vehicle treatment. Even the lowest dose of 0.3 mg/kg was effective in increasing survival to 53%. |
IC 50
HSV-1: 0.02 μM (IC50); HSV-2: 0.02 μM (IC50)
storage
Store at -20°C
References
[1] kleymann g, fischer r, betz u a k, et al. new helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. nature medicine, 2002, 8(4): 392-398.
[2] betz u a k, fischer r, kleymann g, et al. potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor bay 57-1293. antimicrobial agents and chemotherapy, 2002, 46(6): 1766-1772.
BAY-57-1293Supplier
- Tel
- 020-31155029 18902330969
- sales@tomums.cn
- Tel
- 15001988657 15802146997
- info@bookchemicals.com
- Tel
- 13501719342; 13501719342
- wayne.zheng@elucigenbio.com
- Tel
- sales@boylechem.com
- Tel
- 025-83697070 13913916777;
- info@chemlin.com.cn